|
ProBiotix Health PLC said on Tuesday that it has teamed with Uppsala, Sweden-based health company RevivaBio AB to launch a new cholesterol-lowering product. Wakefield, England-based life sciences firm ProBiotix will manufacture the primary finished capsules product using its patented probiotic strain LPLDL. RevivaBio will be responsible for the final packaging of the product. It will be introduced and launched in Sweden and a number of Asia-Pacific markets during the first quarter of 2026 in a capsule dietary supplement under RevivaBio’s own brand. ProBiotix Chief Executive Steen Andersen said: ‘The collaboration marks another important step in our ambition to further our expansion internationally. We are delighted to be working with RevivaBio to develop a new probiotic product, which we believe will prove a highly successful new offering. ‘The cooperation further demonstrates the growing global demand for probiotic products that support heart health, and is expected to help further accelerate our sales growth.’ General manager of RevivaBio Thomas Frid said: ‘Partnering with ProBiotix Health and introducing LPLDL is a major milestone for us. We are proud to strengthen our product portfolio with a world-leading probiotic innovation.’ Shares in Aquis-listed ProBiotix were quoted at 7.75 pence on Tuesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
